13.4  Medical Retina - Diabetes

IVB = Bevacizumab, IVR = Ranibizumab, IVA = Aflibercept, IVTA = Triamcinolone

DCCT [xxxiv]


Strict BSL control in T1DM reduces development and progression of DR, DMO, need for laser, and nephropathy & neuropathy

Hainsworth, D.P., Bebu, I., Aiello, L.P. et al. 2019. Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care 42(5) 875-882.

UKPDS [xxxv]


Strict BSL control in T2DM reduces DR progression and microvascular complications

Tight blood pressure control reduces progression of DR

FIELD [xxxvi,xxxvii]


Fenofibrate in T2DM reduces need for laser treatment for ALL DR (unrelated to concentration of plasma lipids)

ACCORD [xxxviii,xxxix]


Intensive BSL and lipid control reduced rate of progression of retinopathy in those with high risk of cardiovascular disease

Intensive BSL control caused more systemic hypoglycaemic episodes

ETDRS [xl]

Early Treatment Diabetic Retinopathy Study

Macular laser for “CSMO” reduces moderate visual loss

CSMO = 1. DMO within 500 microns of the fovea, 2. Hard exudate within 500 microns of the fovea associated with DMO, 3. Disc area of DMO within disc diameter of the fovea

PRP for high risk PDR; severe NPDR defined (any of: 4 quadrants retinal haemorrhages, 2 quadrants venous beading, 1 IRMA)

PRP can worsen DMO in the short-term

DRS [xli]

Diabetic Retinopathy Study

PRP for high risk PDR halves risk of severe VA loss, causes macular oedema

DRVS [xlii]

Diabetic Retinopathy Vitrectomy Study

“Early” (1 - 6 months) vitrectomy useful for severe VH

Protocol I [xliii,xliv]

Focal/grid laser vs IVR + prompt laser vs IVR + deferred laser vs IVTA + prompt laser

IVR + prompt or deferred laser better than focal/grid laser alone

IVTA + prompt laser better than focal/grid laser alone in pseudophakes but causes IOP rise

5 Year results: IVR + prompt laser no better than IVR + deferred laser

Bressler, S.B., Glassman, A.R., Almukhtar, T. et al. 2016. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. American Journal of Ophthalmology 164 57-68.

Elman, M.J., Ayala, A., Bressler, N.M. et al. 2015. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology (Rochester, Minn) 122(2) 375-381.

Protocol T [xlv]


IVR = IVA = IVB for DMO when VA ≥ 6/12 (20/40)

At 1 year: IVA superior for DMO when VA ≤ 6/15 (20/50)

At 2 years: IVA no longer superior for DMO when VA ≤ 6/15 (20/50)

Diabetic Retinopathy Clinical Research, N., Wells, J.A., Glassman, A.R. et al. 2015. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England Journal of Medicine 372(13) 1193-1203.


All rights reserved. No part of this publication which includes all images and diagrams may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the authors, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law.

Vitreoretinal Surgery Online
This open-source textbook provides step-by-step instructions for the full spectrum of vitreoretinal surgical procedures. An international collaboration from over 90 authors worldwide, this text is rich in high quality videos and illustrations.


Website by WebInjection